Summary
Thein vivo effects of two GABA-elevating drugs with anticonvulsant properties, namely valproic acid (VPA) and aminooxyacetic acid (AOAA), on nerve terminal GABA levels in discrete rat brain regions were studied by means of a newly developed synaptosomal model. The profile of synaptosomal GABA increases obtained with AOAA was quite different from that seen with VPA. Thus, AOAA (30 mg/kg i.p., 2 hours) caused significant increases in olfactory bulb, cortex, hippocampus, thalamus and cerebellum, whereas VPA (200 mg/kg i.p., 0.5 hour) significantly increased GABA also in hypothalamus, substantia nigra and superior and inferior colliculus. In contrast to the regional selectivity of both drugs with respect to synaptosomal GABA levels, AOAA in most regions was more potent than VPA in increasing whole tissue GABA levels determined prior to subcellular fractionation. The data thus demonstrate that comparison of GABA levels in synaptosomal fractions rather than homogenates from discrete brain areas provides a more sensitive index of the action of GABA-elevating drugs administeredin vivo.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anlezark, G., Horton, R. W., Meldrum, B. S., Sawaya, M. C. B.: Anticonvulsant action of ethanolamine-O-sulphate and di-n-propylacetate and the metabolism ofγ-aminobutyric acid (GABA) in mice with audiogenic seizures. Biochem. Pharmacol.25, 413–417 (1976).
Bernasconi, R., Schmutz, M., Martin, P., Hauser, K.: GABA hypothesis for the mechanism of action of antiepileptic drugs: Its usefulness and limitations. In: Neurotransmitters, Seizures, and Epilepsy II (Engel, J., Fariello, R. G., Lloyd, K. G., Morselli, P. L., Quesney, L. F., eds.), pp. 95–104. New York: Raven. 1984.
Chapman, A., Keane, P. E., Meldrum, B. S., Simiand, J., Vernieres, J. C.: Mechanism of anticonvulsant action of valproate. Progr. Neurobiol.19, 315–359 (1982).
Iadarola, M.J., Gale, K.: Dissociation between drug-induced increases in nerve terminal and non-nerve terminal pools of GABAin vivo. Europ. J. Pharmacol.59, 125–129 (1979).
Iadarola, M.J., Gale, K.: Substantia nigra: Site of anticonvulsant activity mediated byγ-aminobutyric acid. Science218, 1237–1240 (1982).
Iadarola, M.J., Raines, A., Gale, K.: Differential effects of n-dipropylacetate and amino-oxyacetic acid onγ-aminobutyric acid levels in discrete areas of rat brain. J. Neurochem.33, 1119–1123 (1979).
Kuriyama, K., Roberts, E., Rubinstein, M. K.: Elevation ofγ-aminobutyric acid in brain with amino-oxyacetic acid and susceptibility to convulsive seizures in mice: A quantitative re-evaluation. Biochem. Pharmacol.15, 221–236 (1966).
Lamar, C., jr.: Mercaptopropionic acid: A convulsant that inhibits glutamate decarboxylase. J. Neurochem.17, 165–170 (1970).
Löscher, W.: A comparative study of the pharmacology of inhibitors of GABA-metabolism. Naunyn-Schmiedeberg's Arch. Pharmacol.315, 119–128 (1980).
Löscher, W.: Biochemical pharmacology of inhibitors of GABA metabolism and valproic acid. In: Neurotransmitters, Seizures, and Epilepsy (Morselli, P. L., Lloyd, K. G., Löscher, W., Meldrum, B. S., Reynolds, E. H., eds.), pp. 93–102. New York: Raven. 1981 a.
Löscher, W.: Effect of inhibitors of GABA aminotransferase on the metabolism of GABA in brain tissue and synaptosomal fractions. J. Neurochem.36, 1521–1527 (1981 b).
Löscher, W.: Valproate induced changes in GABA metabolism at the subcellular level. Biochem. Pharmacol.30, 1364–1366 (1981 c).
Löscher, W.: Valproic acid. In: Handbook of Experimental Pharmacology-Antiepileptic Drugs (Frey, H.-H., Janz, D., eds.), pp. 507–536. Berlin-Heidelberg-New York-Tokyo: Springer. 1985.
Löscher, W., Vetter, M., Müller, F., Böhme, G., Stoltenburg-Didinger, G.: Development of a synaptosomal model to determine drug-inducedin vivo changes in GABA-levels of nerve endings in 11 brain regions of the rat. Neurochem. Int.6, 441–451 (1984).
Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R.J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem.193, 265–275 (1951).
Markwell, M. A. K., Haas, S. M., Bieber, L. L., Tolbert, N. E.: A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem.87, 206–210 (1978).
Patsalos, P. N., Lascelles, P. T.: Changes in regional brain levels of amino acid putative neurotransmitters after prolonged treatment with the anticonvulsant drugs diphenylhydantoin, phenobarbitone, sodium valproate, ethosuximide, and sulthiame in the rat. J. Neurochem.36, 688–695 (1981).
Pinder, R. M., Brodgen, R. N., Speight, T. M., Avery, G. S.: Sodium valproate: A review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs13, 81–123 (1977).
Simler, S., Ciesielski, L., Maitre, M., Randrianarisoa, H., Mandel, P.: Effect of sodium n-dipropylacetate on audiogenic seizures and brainγ-aminobutyric acid level. Biochem. Pharmacol.22, 1701–1708 (1973).
Taberner, P. V., Charington, C. B., Unwin, J. W.: Effects of GAD and GABA-T inhibitors on GABA metabolismin vivo. Brain Res. Bull.5, Suppl. 2, 621–625 (1980).
Tibbles, J. A. R., McGreal, D. A.: Trial of aminooxyacetic acid, an anticonvulsant. Can. med. Ass. J.88, 881–886 (1963).
Wood, J. D., Kurylo, E.: Amino acid content of nerve endings (synaptosomes) in different regions of brain: Effects of gabaculine and isonicotinic acid hydrazide. J. Neurochem.42, 420–425 (1984).
Wood, J. D., Russell, M. P., Kurylo, E., Newstead, J. D.: Stability of synaptosomal GABA levels and their use in determining thein vivo effects of drugs: Convulsant agents. J. Neurochem.33, 61–68 (1979).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Löscher, W., Vetter, M., Böhme, G. et al. In vivo effects of anticonvulsant drugs on nerve terminal (synaptosomal) GABA levels in 11 brain regions of the rat. J. Neural Transmission 63, 157–167 (1985). https://doi.org/10.1007/BF01252615
Issue Date:
DOI: https://doi.org/10.1007/BF01252615